Table 2.

Oligosaccharides obtained from the total nonacid glycosphingolipid fractions from human stomach by hydrolysis with endoglycoceramidase II from Rhodococcus spp. and characterized by LC-ESI/MS and MS²

Abbreviation	Structure	O(Rh+)P	A(Rh+)P	A(Rh+)p	A(Rh+)P case 3a	A(Rh+)P case 4a
Gb3	Galα4Galβ4Glc	+	+	−	−	−
Gb4	GalNAcβ3Galα4Galβ4Glc	+	+	−	−	−
Leb-6b	Fucα2Galβ3 (Fucα4)GlcNAcβ3Galβ4Glc	−	+	+	+	+
Lex-5	Galβ4 (Fucα3)GlcNAcβ3Galβ4Glc	+	+	+	+	+
Lea-5	Galβ3 (Fucα4)GlcNAcβ3Galβ4Glc	+	+	+	+	+
Ley-6	Fucα2Galβ4 (Fucα3)GlcNAcβ3Galβ4Glc	+	+	+	+	+
H5-1	Fucα2Galβ3GlcNAcβ3Galβ4Glc	−	+	−	−	−
Lc4	Galβ3GlcNAcβ3Galβ4Glc	−	+	+	−	+
nLc4	Galβ4GlcNAcβ3Galβ4Glc	+	+	+	+	+
H5-2	Fucα2Galβ4GlcNAcβ3Galβ4Glc	+	+	+	+	+
x2	GalNAcβ3Galβ4GlcNAcβ3Galβ4Glc	+	+	+	+	+
nLc6	Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glc	+	+	+	−	−
H7-2	Fucα2Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glc	+	+	+	−	−
A6-2	GalNAcα3 (Fucα2)Galβ4GlcNAcβ3Galβ4GlcNAcβ3Galβ4Glc	−	+	+	+	+

^a Fractions from human gastric mucosa.

^b The compounds in boldface type have been characterized as H. pylori binding in previous studies (summarized in Table 1).